Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares increased 9.18% to $17. The company on Apr. 7 reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate (ADC) that targets the protein TIM-1 (T cell immunoglobulin and mucin domain). TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas. It is associated with kidney injury and the shedding of its ectodomain is a predictive biomarker for tumor progression. TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The data were presented in a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX), shares after opening at $17.08 moved to $17.20. on last trade day and at the end of the day closed at $15.62. Company price to sales ratio in past twelve months was calculated as 340.02 and price to cash ratio as 4.60. Celldex Therapeutics, Inc. (NASDAQ:CLDX), showed a negative weekly performance of 4.70%.
Investors eyeing a purchase of Horizon Pharma (Symbol: HZNP) shares, but cautious about paying the going market price of $14.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $10 strike, which has a bid at the time of this writing of $1.20. Collecting that bid as the premium represents a 12% return against the $10 commitment, or a 19.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost ). Horizon Pharma Inc (NASDAQ:HZNP), shares fell 1.26% in last trading session and ended the day on $13.05. Horizon Pharma Inc (NASDAQ:HZNP), return on equity ratio is recorded as -340.20% and its return on assets is -80.60%. Horizon Pharma Inc (NASDAQ:HZNP), yearly performance is 422.00%.
Galena Biopharma Inc (NASDAQ:GALE)’s shares jumped 2.21% to $2.31. The company announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY. Galena Biopharma Inc (NASDAQ:GALE), shares moved down 7.30% in last trading session and was closed at $2.16, while trading in range of $ 2.11 – 2.39. Galena Biopharma Inc (NASDAQ:GALE), year to date (YTD) performance is -56.45%.
Shares of security software vendor FireEye Inc (NASDAQ:FEYE) jumped Tuesday following positive rating of the stock by analysts at Wedbush. The analysts upgraded the stock to outperform from neutral and issued price target of $62 per share. The new price target shows potential upside of 23 percent from the previous closing price. FireEye Inc (NASDAQ:FEYE), weekly performance is -9.31%. On last trading day company shares ended up $49.75. FireEye Inc (NASDAQ:FEYE), distance from 50-day simple moving average (SMA50) is -30.47%. Analysts mean target Price for the company is $77.00.